コンテンツへスキップ

GeneFrontier ジーンフロンティア株式会社

  • Solutions
    • Koutai Shokunin
      • Overview
      • Price
      • Flow
    • PUREfrex®
      • Overview
      • Lineup
      • Technology
    • PUREfrex® RD
      • Overview
    • Drug Discovery
      • Overview
  • Support
    • Downloads
      • Koutai Shokunin
      • PUREfrex®
      • PUREfrex® RD
    • Cases
      • Koutai Shokunin
      • PUREfrex®
      • PUREfrex® RD
    • News
      • Exhibition
      • Campaign
      • Others
    • FAQ
      • Koutai Shokunin
      • Purefrex®
      • PUREfrex® RD
  • Company
    • Intoroduction
    • Corporate Profile
    • Access
    • Partners
  • Contact
    • General Contact Form
    • Koutai Shokunin Contact Form
    • PUREfrex® Contact Form
検索 検索

日本語

  • 日本語
English
ジーンフロンティア株式会社

GeneFrontier
Innovative Solution Provider in Protein Engineering and Biologics

Detail
抗体職人

HuCAL® Custom Monoclonal Antibody Generation

PUREfrex

Reconstitud cell-free protein synthesis kit

Solutions

  • Koutai Shokunin

  • PUREfrex®

  • PUREfrex® RD

  • Drug Discovery

Koutai Shokunin

  • Overview
  • Price
  • Flow
  • Cases
  • Publications
  • FAQ
  • Contact
Detail

PUREfrex®

  • Overview
  • Lineup
  • Technology
  • Cases
  • Publications
  • FAQ
  • Contact
Detail

PUREfrex® RD

  • Overview
  • Cases
  • Publications
  • FAQ
  • Contact
Detail

Drug Discovery

  • Overview
  • Contact
Detail

News

  • Exhibition

    Exhibition booth and Poster presentation at Cell Free Systems Conference

    2019.12.10
  • Exhibition

    GeneFrontier presented in the poster session for PEGS Boston

    2019.04.26
  • Exhibition

    PepTalk-The Protein Science Week

    2018.01.15
  • Others

    PUREfrex® 2.1 is newly launched

    2017.12.25
  • Exhibition

    GeneFrontier presented in the poster session for PEGS Boston

    2015.05.14
More

Cases

  • PUREfrex®

    Influence of reducing reagents on the redox state

    2021.01.27
  • PUREfrex®

    Improvement of specific activity by methylation of release factors (RF1 and RF2)

    2021.01.26
  • PUREfrex®

    Improvement of the translation efficiency of consecutive proline residue-containing proteins by EF-P

    2020.07.30
  • PUREfrex®

    Synthesis of proteins containing disulfide bonds with PDI and DsbC

    2019.11.01
  • PUREfrex® RD

    PUREfrex® RD: the unique antibody engineering method based on Ribosome Display with PUREfrex®

    2014.09.26
More
  • Solutions
    • Koutai Shokunin
    • PUREfrex®
    • PUREfrex® RD
    • Drug Discovery
  • Support
    • Downloads
    • Cases
    • News
    • FAQ
  • Company
    • Intoroduction
    • Corporate Profile
    • Access
    • Partners
  • Contact
    • General Contact Form
    • Koutai Shokunin Contact Form
    • PUREfrex® Contact Form
  • Recruit
  • Privacy Policy
Copyright © 2021, GeneFrontier Corporation All rights reserved.